Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

The Merck & Co drug's first successful phase 3 study might not be all it’s cracked up to be.

The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.

In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.

But late-breaking data raise questions about lack of a dose response.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.